Plain-English translation of NCT07453004 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This clinical trial is testing a new medication called to see if it can help people with acute gout attacks — the sudden, painful episodes when gout flares up. The medication is given as a single intravenous infusion. Researchers want to compare how well this new treatment works compared to a standard steroid injection that doctors currently use.
Some people with gout don't respond well to or can't tolerate the usual medications like colchicine or NSAIDs (anti-inflammatory painkillers). This trial is exploring whether this new medication could be a better option for those patients during their most painful gout flares.
You likely qualify if…
You likely don't qualify if…
You would receive either the new medication () or a standard steroid injection as a single dose. The trial includes an interim analysis after the first 60 participants complete their initial pain assessment at 72 hours, which may affect how many more participants are enrolled. You would be monitored for how well the treatment reduces your pain, any side effects, how your body processes the medication, and whether your immune system reacts to it. The study is double-blind, meaning neither you nor the researchers will know which treatment you received until the trial ends.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
China